Paper Details

  1. Home
  2. Paper Details

Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome.

Author: CombalbertJean, FauserBart C J M, FraserGraeme L, GriesingerGeorg, HoveydaHamid R, LademacherChristopher, LavenJoop, Obermayer-PietschBarbara, PintiauxAxelle, RamaelSteven, TimmermanDirk

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Fezolinetant, a neurokinin 3 (NK3) receptor antagonist, suppressed hyperandrogenism and reduced the LH-to-FSH ratio in women with PCOS.
Paper Details　
Original Abstract of the Article :
CONTEXT: Polycystic ovary syndrome (PCOS), a highly prevalent endocrine disorder characterized by hyperandrogenism, is the leading cause of anovulatory infertility. OBJECTIVE: This proof-of-concept study evaluated clinical efficacy and safety of the neurokinin 3 (NK3) receptor antagonist fezolineta...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372662/

データ提供：米国国立医学図書館（NLM）

Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome

This study explores the potential of a novel drug, fezolinetant, for the treatment of polycystic ovary syndrome (PCOS), a common endocrine disorder that affects millions of women worldwide. It's like discovering a new oasis in the vast desert of hormone imbalances - offering potential solutions for a challenging condition. The authors conducted a randomized controlled trial to evaluate the efficacy and safety of fezolinetant in women with PCOS, focusing on its ability to suppress hyperandrogenism and improve hormonal balance.

A New Oasis in the Desert of PCOS Treatment

This study offers a promising new approach to treating PCOS, highlighting the potential benefits of targeting the neurokinin 3 receptor. It's like finding a hidden oasis in a desert - offering a potential solution for a complex and often challenging condition. The study's findings encourage further research into the therapeutic potential of fezolinetant and its potential to improve the lives of women with PCOS.

Navigating the Sands of PCOS Management

This research provides valuable insights into the potential for new treatments for PCOS, offering a beacon of hope for women seeking relief from this challenging condition. It's like having a guidebook for navigating a complex desert - helping to make informed decisions and achieve optimal outcomes. The study encourages further research into the therapeutic potential of fezolinetant and its potential to improve the lives of women with PCOS.

Dr.Camel's Conclusion

This randomized controlled trial sheds light on the potential of fezolinetant for treating PCOS, offering a glimmer of hope in the desert of hormonal imbalances. It's like discovering a new oasis - a potential solution for a challenging condition that affects millions of women worldwide. The study's findings encourage further research into the therapeutic potential of fezolinetant and its potential to improve the lives of women with PCOS.
Date :
  1. Date Completed 2021-11-04
  2. Date Revised 2021-12-03
Further Info :

Pubmed ID

34000049

DOI: Digital Object Identifier

PMC8372662

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.